Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models
1996

Using Serum Albumin to Deliver Zinc Phthalocyanine for Cancer Treatment

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): C Larroquel, A Pelegrin, JE Van Lier

Primary Institution: MRC Group in the Radiation Sciences, Faculty of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada

Hypothesis

Can zinc phthalocyanine (ZnPc) bound to bovine serum albumin (BSA) effectively control tumors in mice through photodynamic therapy?

Conclusion

The study found that ZnPc-BSA preparations can effectively control tumors in mice without causing significant liver toxicity.

Supporting Evidence

  • ZnPc-BSA preparations provided tumor control in two different mouse models.
  • The study demonstrated the absence of hepatic toxicity from the ZnPc-BSA preparation.
  • ZnPc readily redistributes over the serum high-density lipoprotein fraction after administration.

Takeaway

This study shows that a special mix of a cancer-fighting dye and a protein can help treat tumors in mice without hurting their livers.

Methodology

Mice with tumors were treated with ZnPc-BSA and then exposed to light to activate the treatment, with tumor responses measured over time.

Limitations

The study primarily involved animal models, which may not fully represent human responses.

Participant Demographics

The study used Balb/c and nude mice, specifically 7- to 9-week-old female Swiss nu/nu mice.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication